BILL ANALYSIS Ó
AB 1823
Page 1
CONCURRENCE IN SENATE AMENDMENTS
AB
1823 (Bonilla)
As Amended August 19, 2016
Majority vote
--------------------------------------------------------------------
|ASSEMBLY: |80-0 |(June 1, 2016) |SENATE: |39-0 |(August 23, |
| | | | | |2016) |
| | | | | | |
| | | | | | |
--------------------------------------------------------------------
Original Committee Reference: HEALTH
SUMMARY: Requests the University of California (UC) to
establish and designate an institute or office with the
authority to solicit and receive funds from business, industry,
foundations, and other private and federal sources for the
purpose of administering the Cancer Clinical Trials Program (the
program) to increase patient access to cancer clinical trials.
Establishes a five-member board to administer the program.
Authorizes the UC to use its own state source funds for
oversight and administration of the program relating to the
initial start-up costs of the program only, provided the UC is
reimbursed from federal and private sources funds. Requires the
program, on receipt of funds totaling $500,000, to establish the
Cancer Clinical Trials Grant Program (Grant Program) to increase
patient access to cancer clinical trials in underserved or
disadvantaged communities and populations. Limits
administrative expenses to 20% of funds that are made available,
but authorizes the use of more than 20% for the first year of
the program. Allows UC to discontinue the program for various
AB 1823
Page 2
reasons.
The Senate amendments clarify requirements for persons appointed
to the board, and provides for the use of funds for
administrative costs, as specified.
FISCAL EFFECT: According to the Senate Appropriations
Committee:
1)Start-up: Unknown one-time General Fund cost pressure for the
UC to provide oversight and administration of the Program
related to initial start-up activities. These costs are
required to be reimbursed by moneys donated to the fund
(federal or private funds) prior to awarding grants, thereby
offsetting the use of state funds. This bill also provides
that if the UC determines at any time that the moneys in the
fund are insufficient to establish or sustain the Program, it
may be terminated.
2)Unknown federal or private funds to administer the program and
award grants. In order to have a viable program and offer
services as described in this bill, UC indicates that funding
would likely need to be in the millions. The scope of the
program, including the number of grantees, grant amounts, and
administrative support to operate the program would depend
upon future donations.
COMMENTS: The author states that this bill seeks to remedy the
problem of low patient participation in the federal Food and
Drug Administration approved cancer clinical trials. More
importantly, there are a disproportionately low number of
patients in underrepresented communities including African
Americans, Latinos/Hispanics, Asians and Pacific Islanders, and
American Indians. The author asserts this problem will be
addressed by creating a privately funded state grant program to
help patients pay for the ancillary costs associated with
participation in these trials. Some of the barriers to patient
AB 1823
Page 3
participation in clinical trials include the following: lack of
awareness of the available clinical trials, mistrust of research
and the medical system, and loss of income. Clinical trials do
not pay these ancillary costs associated with participation in a
clinical trial such as transportation, hotel stays, and
companion traveling expenses. The costs fall onto the clinical
trial participant who may be unable to pay and therefore, unable
to enroll in the trial.
Analysis Prepared by:
Rosielyn Pulmano / HEALTH / (916) 319-2097 FN:
0003279